Page last updated: 2024-11-06

dihydroxydiphenyl-pyridyl methane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID69046
CHEMBL ID3544537
SCHEMBL ID3615825
MeSH IDM0041929

Synonyms (47)

Synonym
desacetylbisacodyl
einecs 210-039-7
phenol, 4,4'-(2-pyridinylmethylene)bis-
deacetylbisocodyl
phenol, 4,4'-(2-pyridylmethylene)di-
brn 0212040
4,4'-(2-pyridinylmethylene)bisphenol
la-96
deacetylbisacodyl
p,p'-(2-pyridylmethylene)bisphenol
desacetyl-bisacodyl
4,4'-(2-pyridylmethylene)diphenol
dihydroxydiphenyl-pyridyl methane
ddpm
bhpm
4-[(4-hydroxyphenyl)-pyridin-2-ylmethyl]phenol
FT-0665909
SCHEMBL3615825
603-41-8
4-[(4-hydroxyphenyl)(pyridin-2-yl)methyl]phenol
r09078e41y ,
unii-r09078e41y
ec 210-039-7
AKOS024323666
desacetyl bisacodyl
4,4'-dihydroxydiphenyl(2-pyridyl)methane
bis(4-hydroxyphenyl)(2-pyridyl)methane
bis-(p-hydroxyphenyl)pyridyl-2-methane
bisacodyl impurity a [ep impurity]
bisacodyl diphenol
sodium picosulfate impurity b [ep impurity]
4,4'-(2-pyridyl-methylen)-diphenol
DTXSID20209053 ,
CHEMBL3544537
C90507
4,4'-(pyridin-2-ylmethylene)diphenol
bp_34
4,4'-[(pyridin-2-yl)methylene]diphenol
DB14232
Q27287600
deacetyl bisacodyl
AS-83080
CS-0137992
sodium picosulfate impurity b (ep impurity)
bis(p-hydroxyphenyl)pyridyl-2-methane
bisacodyl impurity a (ep impurity)
dtxcid40131544

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Deacetylbisacodyl was more potent than the parent compound and was used to investigate dose-response relationships."( The influence of bisacodyl and deacetylbisacodyl on mucus secretion, mucus synthesis and electrolyte movements in the rat colon in vivo.
Farack, UM; Gruber, E; Loeschke, K, 1985
)
0.27
" C(max) was attained approximately 5 h after dosing of Bisa and 9 h after dosing of SPS."( Absence of excretion of the active moiety of bisacodyl and sodium picosulfate into human breast milk: an open-label, parallel-group, multiple-dose study in healthy lactating women.
de Kruif, S; Friedrich, C; Gessner, U; Mandel, K; Richter, E; Trommeshauser, D; van Iersel, T, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (56.25)18.7374
1990's4 (25.00)18.2507
2000's0 (0.00)29.6817
2010's2 (12.50)24.3611
2020's1 (6.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.58 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]